KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $117000.0.

  • Amneal Pharmaceuticals' Other Operating Expenses fell 8864.08% to $117000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 10476.76%. This contributed to the annual value of -$96.7 million for FY2024, which is 76697.94% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Other Operating Expenses is $117000.0, which was down 8864.08% from $390000.0 recorded in Q2 2025.
  • Amneal Pharmaceuticals' Other Operating Expenses' 5-year high stood at $13.4 million during Q4 2023, with a 5-year trough of -$251.9 million in Q2 2022.
  • For the 5-year period, Amneal Pharmaceuticals' Other Operating Expenses averaged around -$21.7 million, with its median value being -$699000.0 (2024).
  • In the last 5 years, Amneal Pharmaceuticals' Other Operating Expenses plummeted by 3156666.67% in 2021 and then soared by 16648.25% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Other Operating Expenses stood at -$6.0 million in 2021, then crashed by 234.9% to -$20.1 million in 2022, then soared by 166.48% to $13.4 million in 2023, then tumbled by 113.35% to -$1.8 million in 2024, then surged by 106.56% to $117000.0 in 2025.
  • Its Other Operating Expenses was $117000.0 in Q3 2025, compared to $390000.0 in Q2 2025 and $5.1 million in Q1 2025.